Topical administration of diminazene aceturate decreases inflammation in endotoxin-induced uveitis

Molecular Vision

Volumn 21, Issue , 2015, Pages 403-411

  Zheng, Changwei ^a   Lei, Chunyan ^a   Chen, Zihe ^a   Zheng, Shijie ^a   Yang, Hongxia ^a   Qiu, Yiguo ^a   Lei, Bo ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; CD11B ANTIGEN; CYCLOOXYGENASE 2; DEXAMETHASONE; DIMINAZENE ACETURATE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; DIMINAZENE; DIPEPTIDYL CARBOXYPEPTIDASE; EYE DROPS; LIPOPOLYSACCHARIDE; NOS2 PROTEIN, RAT; PTGS2 PROTEIN, RAT; RELA PROTEIN, RAT; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTOXIN-INDUCED UVEITIS; ENZYME ACTIVATION; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; INTRAOCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; UVEA; UVEITIS;

ADMINISTRATION, OPHTHALMIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; AQUEOUS HUMOR; CYCLOOXYGENASE 2; DEXAMETHASONE; DIMINAZENE; FEMALE; GENE EXPRESSION; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; NITRIC OXIDE SYNTHASE TYPE II; OPHTHALMIC SOLUTIONS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; UVEA; UVEITIS;

EID: 84927667478     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chang JH, Wakefield D. Uveitis: a global perspective. Ocul Immunol Inflamm 2002; 10:263-79. [PMID: 12854035].
2. Kuriakose S, Muleme HM, Onyilagha C, Singh R, Jia P, Uzonna JE. Diminazene aceturate (Berenil) modulates the host cellular and inflammatory responses to Trypanosoma congolense infection. PLoS ONE 2012; 7:e48696-[PMID: 23144931].
3. Qi Y, Zhang J, Cole-Jeffrey CT, Shenoy V, Espejo A, Hanna M, Song C, Pepine CJ, Katovich MJ, Raizada MK. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension 2013; 62:746-52. [PMID: 23959549].
4. Kuriakose S, Muleme H, Onyilagha C, Okeke E, Uzonna JE. Diminazene aceturate (Berenil) modulates LPS induced pro-inflammatory cytokine production by inhibiting phosphorylation of MAPKs and STAT proteins. Innate Immunity. 2014; 20:760-73. [PMID: 24179040].
5. Qiu Y, Shil PK, Zhu P, Yang H, Verma A, Lei B, Li Q. Angiotensin-Converting Enzyme 2 (ACE2) Activator Diminazene Aceturate Ameliorates Endotoxin-Induced Uveitis in Mice. Invest Ophthalmol Vis Sci 2014; 55:3809-18. [PMID: 24854854].
6. Kracht M, Saklatvala J. Transcriptional and post-transcriptional control of gene expression in inflammation. Cytokine 2002; 20:91-106. [PMID: 12453467].
7. Srivastava SK, Ramana KV. Focus on molecules: nuclear factor-kappaB. Exp Eye Res 2009; 88:2-3. [PMID: 18472097].
8. Kitamei H, Iwabuchi K, Namba K, Yoshida K, Yanagawa Y, Kitaichi N, Kitamura M, Ohno S, Onoé K. Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate. J Leukoc Biol 2006; 79:1193-201. [PMID: 16574770].
9. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298:1911-2. [PMID: 12471242].
10. Bhattacherjee P, Williams RN, Eakins KE. An evaluation of ocular inflammation following the injection of bacterial endotoxin into the rat foot pad. Invest Ophthalmol Vis Sci 1983; 24:196-202. [PMID: 6337969].
11. McMenamin PG, Crewe J. Endotoxin-induced uveitis. Kinetics and phenotype of the inflammatory cell infiltrate and the response of the resident tissue macrophages and dendritic cells in the iris and ciliary body. Invest Ophthalmol Vis Sci 1995; 36:1949-59. [PMID: 7657537].
12. de Vos AF, van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994; 35:1100-6. [PMID: 8125720].
13. Planck SR, Huang XN, Robertson JE, Rosenbaum JT. Cytokine mRNA levels in rat ocular tissues after systemic endotoxin treatment. Invest Ophthalmol Vis Sci 1994; 35:924-30. [PMID: 8125755].
14. Iwama D, Miyahara S, Tamura H, Miyamoto K, Hirose F, Yoshimura N. Lack of inducible nitric oxide synthases attenuates leukocyte-endothelial cell interactions in retinal microcirculation. Br J Ophthalmol 2008; 92:694-8. [PMID: 18441175].
15. Smith JR, Hart PH, Williams KA. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol Cell Biol 1998; 76:497-512. [PMID: 9893027].
16. Yoshida M, Yoshimura N, Hangai M, Tanihara H, Honda Y. Interleukin-1 alpha, interleukin-1 beta, and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1994; 35:1107-13. [PMID: 8125721].
17. Yadav UC, Srivastava SK, Ramana KV. Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2007; 48:4634-42. [PMID: 17898287].
18. Hoekzema R, Murray PI, van Haren MA, Helle M, Kijlstra A. Analysis of interleukin-6 in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1991; 32:88-95. [PMID: 1987109].
19. Lin T, Qiu Y, Liu Y, Mohan R, Li Q, Lei B. Expression of adiponectin and its receptors in type 1 diabetes mellitus in human and mouse retinas. Mol Vis 2013; 19:1769-78. [PMID: 23922494].
20. Barrios-Rodiles M, Tiraloche G, Chadee K. Lipopolysaccharide modulates cyclooxygenase-2 transcriptionally and posttranscriptionally in human macrophages independently from endogenous IL-1 beta and TNF-alpha. J Immunol 1999; 163:963-9. [PMID: 10395693].
21. Yang S, Lu H, Wang J, Qi X, Liu X, Zhang X. The effect of toll-like receptor 4 on macrophage cytokines during endotoxin induced uveitis. Int J Mol Sci 2012; 13:7508-20. [PMID: 22837708].
22. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990; 4:2860-7. [PMID: 2199284].
23. Robinson AP, White TM, Mason DW. Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3. Immunology 1986; 57:239-47. [PMID: 3512425].
24. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107:7-11. [PMID: 11134171].
25. Cordle SR, Donald R, Read MA, Hawiger J. Lipopolysaccharide induces phosphorylation of MAD3 and activation of c-Rel and related NF-kappa B proteins in human monocytic THP-1 cells. J Biol Chem 1993; 268:11803-10. [PMID: 8505309].
26. Suzuki Y, Ohgami K, Shiratori K, Jin XH, Ilieva I, Koyama Y, Yazawa K, Yoshida K, Kase S, Ohno S. Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-kappaB signaling pathway. Exp Eye Res 2006; 82:275-81. [PMID: 16126197].
27. Li S, Lu H, Hu X, Chen W, Xu Y, Wang J. Expression of TLR4-MyD88 and NF-kappaB in the iris during endotoxin-induced uveitis. Mediators Inflamm 2010; 2010:748218-[PMID: 20847811].
28. Wang JX, Hou LF, Yang Y, Tang W, Li Y, Zuo JP. SM905, an artemisinin derivative, inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kappaB pathways in RAW 264.7 macrophages. Acta Pharmacol Sin 2009; 30:1428-35. [PMID: 19801997].
29. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005; 1754:253-62. [PMID: 16198162].
30. Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen 2011; 16:878-85. [PMID: 21859683].
31. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, Bretas TL, Bader M, de Sousa LP, da Silva TA, dos Santos RA, Simões e Silva AC, Teixeira MM. Anti-inflammatory effects of the activation of the angiotensin-(1–7) receptor, MAS, in experimental models of arthritis. J Immunol 2010; 185:5569-76. [PMID: 20935211].
32. El-Hashim AZ, Remo WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF. Angiotensin-(1–7) inhibits allergic inflammation, via the MAS1 receptor, throughsuppression of ERK1/2- and NF-kappaB-dependent pathways. Br J Pharmacol 2012; 166:1964-76. [PMID: 22339213].
33. Su Z, Zimpelmann J, Burns KD. Angiotensin-(1–7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 2006; 69:2212-8. [PMID: 16672906].
34. Jiang T, Gao L, Guo J, Lu J, Wang Y, Zhang Y. Suppressing inflammation by inhibiting the NF-kappaB pathway contributes to the neuroprotective effect of angiotensin-(1–7) in rats with permanent cerebral ischaemia. Br J Pharmacol 2012; 167:1520-32. [PMID: 22817481].
35. Vaajanen A, Lakkisto P, Virtanen I, Kankuri E, Oksala O, Vapaatalo H, Tikkanen I. Angiotensin receptors in the eyes of arterial hypertensive rats. Acta Ophthalmol 2010; 88:431-8. [PMID: 19758401].
36. Huang HS, Schoenwald RD, Lach JL. Corneal penetration behavior of beta-blocking agents II: Assessment of barrier contributions. J Pharm Sci 1983; 72:1272-9. [PMID: 6139472].
37. Sharma SP, Bansal GC. Chemoprophylaxis with diminazene aceturate in experimental Babesia bigemina infection in cattle. Res Vet Sci 1984; 37:126-7. [PMID: 6473911].
38. Lewis KM, Cohn LA, Birkenheuer AJ, Papich MG. Pharmacokinetics of diminazene diaceturate in healthy cats. J Vet Pharmacol Ther 2012; 35:608-10. [PMID: 22212100].